CAS 202914-84-9

Lomitapide mesylate

Description:

Lomitapide mesylate is a pharmaceutical compound primarily used in the treatment of hyperlipidemia, particularly in patients with familial hypercholesterolemia. It functions as an inhibitor of microsomal triglyceride transfer protein (MTP), which plays a crucial role in the assembly and secretion of lipoproteins in the liver. By inhibiting MTP, Lomitapide reduces the production of very low-density lipoprotein (VLDL) and subsequently lowers levels of low-density lipoprotein (LDL) cholesterol in the bloodstream. The substance is typically administered orally and is characterized by its mesylate salt form, which enhances its solubility and bioavailability. Lomitapide mesylate is known for its potential side effects, including gastrointestinal disturbances and liver enzyme elevations, necessitating regular monitoring of liver function during treatment. Its chemical structure includes a specific arrangement of functional groups that contribute to its pharmacological activity. Overall, Lomitapide mesylate represents a targeted approach to managing cholesterol levels in patients with genetic predispositions to high cholesterol.

Formula: C₃₉H₃₇F₆N₃O₂·xCH₄O₃S

InChI: InChI=1S/C39H37F6N3O2.CH4O3S/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45;1-5(2,3)4/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49);1H3,(H,2,3,4)

InChI key: InChIKey=QKVKOFVWUHNEBX-UHFFFAOYSA-N

SMILES: C(CCCN1CCC(NC(=O)C2=C(C=CC=C2)C3=CC=C(C(F)(F)F)C=C3)CC1)C4(C(NCC(F)(F)F)=O)C=5C(C=6C4=CC=CC6)=CC=CC5.S(C)(=O)(=O)O

Synonyms:

• 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]car bonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate
• 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate
• 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate (1:?)
• BMS 201038 methanesulfonic acid salt
• Bms 201038-04
• Juxtapid
• Lomitapide mesylate

Lomitapide (mesylate)

CAS: 202914-84-9

Formula: C₄₀H₄₁F₆N₃O₅S

Purity: 98%

Color and Shape: Solid

Molecular weight: 789.8261

Ref: IN-DA00BF66

Lomitapide Mesylate

CAS: 202914-84-9

Lomitapide Mesylate

Purity: ≥98%

Molecular weight: 789.83g/mol

Ref: 54-BUP09669

Lomitapide Mesylate

CAS: 202914-84-9

Lomitapide Mesylate (BMS-201038 mesylate) is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.

Formula: C₄₀H₄₁F₆N₃O₅S

Purity: 99.92%

Color and Shape: Solid

Molecular weight: 789.83

Ref: TM-T2545

Lomitapide mesylate

CAS: 202914-84-9

Formula: C₃₉H₃₇F₆N₃O₂CH₄O₃S

Molecular weight: 693.73 : 96.10

Ref: ST-EA-CP-L114001

Lomitapide mesylate

CAS: 202914-84-9

Lomitapide mesylate is a drug used to treat familial hypercholesterolemia. It is an ATP-binding cassette transporter inhibitor and can be used to lower cholesterol levels in patients with homozygous familial hypercholesterolemia. Lomitapide mesylate has been shown to reduce LDL-C levels by up to 50% in patients with this condition. The drug has a number of side effects, such as skin cancer, which may be due to the inhibition of chemoattractant protein signalling pathways. Side effects are usually mild and transient, but may include hepatic dysfunction and metabolic disorders. Lomitapide mesylate is metabolized by CYP3A4 enzyme and its plasma concentration may be increased if taken concurrently with drugs that inhibit this enzyme (e.g., diltiazem).

Formula: C₄₀H₄₁F₆N₃SO₅

Purity: Min. 95%

Molecular weight: 789.83 g/mol

Ref: 3D-CIA91484